Our expert analytical scientists will work with you to design custom methodologies to help you meet your objectives.   We will help you anticipate scientific or regulatory challenges, offer strategic solutions to enable you to make critical strategic decisions, and will report your results in an appropriate format.   We've developed many novel methodologies from in vitro CYP-activity assays to environmental contamination monitoring (swipe testing) methods for our clients.   We perform routine analyses untilizing these methodologies; exclusivity options are available.
OpAns began performing HPLC-MS/MS steroid measurements in support of pharmaceutical treatments of steroid mediated cancers. As a result, custom CYP-activity assays were developed, validated, and routine studies are conducted.
Example Methodology:   CYP17 activity assays (hydroxylase and lyase) to evaluate drug as potential selective inhibitors
Background: Inhibition of the key enzyme which catalyzes the biosynthesis of androgens from pregnane precursors, 17α-hydroxy/17,20-lyase (CYP17) could prevent androgen production from all sources.   Thus, total ablation of androgen production by potent CYP17 inhibitors may provide effective treatment of prostate cancer patients.*
OpAns has developed and validated a novel HPLC-MS/MS method; we routinely prepare and ship sample collection kits and run samples from workplace environments (e.g., hospitals and clinics).
Example Metholology:   Antineoplastic agents (i.e., 5-fluorouracil, ifosfamide, cyclophosphamide, methotrexate, platinum analogues, docetaxel, paclitaxel, busulfan, etoposide, cytarabine, doxorubicin, daunorubicin, vincristine, gemcitabine, irinotecan, mitomycin C, and 5-azacytidine)
* Vasaitis TS, Bruno RD, Njar VC. CYP17 Inhibitors for Prostate Cancer Therapy. J Steroid Biochem Mol Biol. 2011;125(1-2):23-31. doi:10.1016/j.jsbmb.2010.11.005